USANA Health Sciences, Inc. (USNA) CFO Sells $43,285.95 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) CFO G Doug Iiekking sold 387 shares of the firm’s stock in a transaction on Monday, October 29th. The shares were sold at an average price of $111.85, for a total value of $43,285.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

G Doug Iiekking also recently made the following trade(s):

  • On Tuesday, September 4th, G Doug Iiekking sold 2,200 shares of USANA Health Sciences stock. The shares were sold at an average price of $130.08, for a total value of $286,176.00.
  • On Thursday, September 6th, G Doug Iiekking sold 6,570 shares of USANA Health Sciences stock. The shares were sold at an average price of $126.25, for a total value of $829,462.50.

USANA Health Sciences stock opened at $112.59 on Friday. The stock has a market cap of $2.84 billion, a P/E ratio of 23.88 and a beta of 0.80. USANA Health Sciences, Inc. has a 52 week low of $64.20 and a 52 week high of $137.95.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, October 23rd. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. The firm had revenue of $296.80 million during the quarter, compared to analysts’ expectations of $289.54 million. USANA Health Sciences had a return on equity of 30.37% and a net margin of 7.57%. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. As a group, analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current year.

USANA Health Sciences announced that its board has approved a share repurchase program on Tuesday, October 23rd that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the company to buy up to 5.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in shares of USANA Health Sciences by 14.2% during the 1st quarter. BlackRock Inc. now owns 829,290 shares of the company’s stock worth $71,237,000 after acquiring an additional 103,325 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of USANA Health Sciences by 112.0% during the 1st quarter. JPMorgan Chase & Co. now owns 42,276 shares of the company’s stock worth $3,631,000 after acquiring an additional 22,335 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of USANA Health Sciences by 86.1% during the 1st quarter. Sei Investments Co. now owns 4,445 shares of the company’s stock worth $382,000 after acquiring an additional 2,056 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of USANA Health Sciences by 314.6% during the 1st quarter. Millennium Management LLC now owns 84,445 shares of the company’s stock worth $7,254,000 after acquiring an additional 64,078 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of USANA Health Sciences by 40.2% during the 1st quarter. Legal & General Group Plc now owns 5,852 shares of the company’s stock worth $503,000 after acquiring an additional 1,678 shares during the last quarter. Hedge funds and other institutional investors own 51.50% of the company’s stock.

USNA has been the subject of a number of research analyst reports. Pivotal Research restated a “hold” rating and issued a $135.00 price target on shares of USANA Health Sciences in a research report on Wednesday, July 25th. Sidoti upgraded USANA Health Sciences from a “neutral” rating to a “buy” rating in a research report on Thursday, October 25th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Google Finance

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply